In Patients Experiencing Biochemical Failure After Radiotherapy, Pretreatment Risk Group and PSA Velocity Predict Differences in Overall Survival and Biochemical Failure-Free Interval

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 5, 2008, Pages 1295-1301

  Soto, Daniel E ^a   Andridge, Rebecca R ^a   Pan, Charlie C ^a   Williams, Scott G ^b   Taylor, Jeremy M G ^a   Sandler, Howard M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Kinetics; Prostate specific antigen; Prostatic neoplasms; Radiotherapy; Statistics

Indexed keywords

ELECTROTHERAPEUTICS; PEELING; RADIOTHERAPY; SPEED; STATISTICS;

ANDROGEN DEPRIVATION THERAPY (ADT); BIOCHEMICAL FAILURES; ELSEVIER (CO); EXTERNAL BEAM RADIOTHERAPY (EBRT); HIGH RISK PATIENTS; LOCALIZED PROSTATE CANCER; LOW VELOCITIES; OVERALL SURVIVAL (OS); PRE TREATMENTS; PROSTATE CANCER (CAP); PROSTATE SPECIFIC ANTIGEN (PSA); TREATMENT FAILURE;

RISKS;

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RADIATION DOSE; RISK FACTOR; SURVIVAL RATE; TREATMENT FAILURE;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK; TIME FACTORS;

EID: 47349092030     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.02.069     Document Type: Article

References (46)

1. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
2. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
3. Roach III M., Weinberg V., McLaughlin P.W., et al. Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology 61 (2003) 730-735
4. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 79 (1997) 337-344
5. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 281 (1999) 1598-1604
6. Pisansky T.M., Kahn M.J., and Bostwick D.G. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 79 (1997) 2154-2161
7. Kattan M.W., Zelefsky M.J., Kupelian P.A., et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18 (2000) 3352-3359
8. Makarov D.V., Trock B.J., Humphreys E.B., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007) 1095-1101
9. Fukunaga-Johnson N., Sandler H.M., McLaughlin P.W., et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 38 (1997) 311-317
10. Zagars G.K., Pollack A., and von Eschenbach A.C. Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79 (1997) 1370-1380
11. Movsas B., Hanlon A.L., Teshima T., et al. Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer 80 (1997) 1093-1102
12. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
13. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
14. D'Amico A.V., Schultz D., Loffredo M., et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 284 (2000) 1280-1283
15. Crook J., Ludgate C., Malone S., et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 15-23
16. Sengupta S., Myers R.P., Slezak J.M., et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
17. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
18. D'Amico A.V., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 5 Pt 2 (2004) S42-S47
19. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
20. Sengupta S., Blute M.L., Bagniewski S.M., et al. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: Doubling time predicts survival. J Urol 175 (2006) 1684-1690
21. Zagars G.K., and Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44 (1997) 213-221
22. Patel D.A., Presti Jr. J.C., McNeal J.E., et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23 (2005) 6157-6162
23. Petit J.H., Chen M.H., Loffredo M., et al. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer 107 (2006) 2180-2185
24. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
25. Pollack A., Hanlon A.L., Movsas B., et al. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 19-23
26. Kupelian P.A., Buchsbaum J.C., Patel C., et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 52 (2002) 704-711
27. Kwan W., and Pickles T. In regard to Kupelian, et al.: Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. IJROBP 2002;52:704-711. Int J Radiat Oncol Biol Phys 54 (2002) 1577-1579 author reply 1579
28. Sandler H.M., Dunn R.L., McLaughlin P.W., et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48 (2000) 629-633
29. Williams S.G., Duchesne G.M., Millar J.L., et al. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 1082-1087
30. Kwan W., Pickles T., Duncan G., et al. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 60 (2004) 1040-1046
31. Dotan Z.A., Bianco Jr. F.J., Rabbani F., et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 23 (2005) 1962-1968
32. Eggener S.E., Roehl K.A., Yossepowitch O., et al. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol 176 4 Pt 1 (2006) 1399-1403
33. Palma D., Tyldesley S., Blood P., et al. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys 67 (2007) 1425-1429
34. Lee A.K., and D'Amico A.V. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23 (2005) 8192-8197
35. D'Amico A.V., Loffredo M., Renshaw A.A., et al. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 24 (2006) 4190-4195
36. Williams S.G., Taylor J.M., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 24-33
37. Coogan C.L., Latchamsetty K.C., Greenfield J., et al. Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score. BJU Int 96 (2005) 324-327
38. Lee I.H., Roberts R., Shah R.B., et al. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1059-1064
39. Spalding A.C., Daignault S., Sandler H.M., et al. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. Urology 69 (2007) 936-940
40. Beard C.J., Chen M.H., Cote K., et al. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys 58 (2004) 19-24
41. Beard C., Schultz D., Loffredo M., et al. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 403-407
42. D'Amico A.V., Schultz D., Silver B., et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 49 (2001) 679-684
43. D'Amico A.V., Renshaw A.A., Cote K., et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 22 (2004) 3726-3732
44. Nguyen P.L., Chen M.H., Renshaw A.A., et al. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology 70 (2007) 288-293
45. Bates A.T., Pickles T., and Paltiel C. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 148-153
46. Buyyounouski M.K., Hanlon A.L., Horwitz E.M., et al. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int J Radiat Oncol Biol Phys 61 (2005) 1291-1298